Main Article Content

Abstract

This study was designed to evaluate the protective effect of Calocybe indica extract (CLE) on testosterone propionate (TP)-induced hematological changes and oxidative stress in rats. The rats were grouped into six equal groups of ten rats each as follows:(a) control, (b) TP 3 mg/kg only, (c) 3mg/kg TP+ 5 mg/kg finasteride, (d) 3 mg/kg TP+250 mg/kg CLE, (e) 3 mg/kg TP+ 500 mg/kg CLE and (f) 3 mg/kg TP+1000 mg/kg CLE. The rats were administered TP subcutaneously for 28 days to induce benign prostatic hyperplasia (BPH) and simultaneously administered three graded doses of CLE, and finasteride as the standard drug. Hematological parameters, lipid peroxidation, antioxidant enzyme activities and histopathological examination of the prostate were assessed. BPH induction showed higher red blood cells (RBCs) count, haemoglobin (Hb) concentration, packed cell volume (PCV), serum prostate specific antigen (PSA), malondialdehyde (MDA) and lower white blood cell (WBC) count, lymphocyte count as well as lower catalase (CAT) and superoxide dismutase (SOD) activities.  The simultaneous oral administration of CLE with testosterone injection did not significantly lower RBC count, Hb concentration and PCV but significantly lowered serum PSA and MDA. There was also a significantly higher WBC count, lymphocyte count, CAT and SOD activities. The results from this study suggest that dietary consumption of Calocybe indica, a mushroom with high antioxidant activity ameliorated BPH induced oxidative tissue damage and hematological alterations.

Keywords

Antioxidant; Hematology; Hyperplasia; Macrofungi; Prostate‎

Article Details

How to Cite
Onoja, R. I., Ogara, A. L., Ihedioha, J. I., & Shoyinka, S. V. O. (2023). Effects of Calocybe indica Mushroom on Oxidative Stress and Hematological ‎Alterations in Rats with Testosterone-induced Experimental Benign Prostatic ‎Hyperplasia. Sahel Journal of Veterinary Sciences, 20(1), 28-34. https://doi.org/10.54058/saheljvs.v20i1.343

References

  1. Aghazadeh, M., Pastuszak, A.W., Johnson, W.G., McIntyre, ‎M.G., Hsieh, T.M. andLipshultz,L.I. (2015). Elevated ‎dihydrotestosterone is associated with testosterone ‎induced erythrocytosis. J. Urol., 194(1), 160–165. ‎doi.org/10.1016/j.juro.2015.01.038‎
  2. Ahmed Amar, S. A., Eryilmaz, R., Demir, H., Aykan, S. and ‎Demir, C. (2019). Determination of oxidative stress levels ‎and some antioxidant enzyme activities in prostate ‎cancer. Aging Male., 22 (3), 198–206. ‎doi.org/10.1080/13685538.2018.1488955‎
  3. Akbari, F., Azadbakht, M., Gaurav, A., Azimi, F., Mahdizadeh, ‎Z., Vahedi, L., Barzegar Nejad, A., Chabra, A. and ‎Eghbali, M. (2022). Evaluation of the therapeutic effect ‎of the traditional herbal medicine Atrifil and Oshagh gum ‎on testosterone-induced benign prostatic hyperplasia in ‎wistar rats. Adv. Urol., 2022, 5742431. ‎doi.org/10.1155/2022/5742431‎
  4. Al-Sheikh, Y. A. and Ghneim, H. K. (2011). 'The effect of ‎micronutrients on superoxide dismutase in senescent ‎fibroblasts'. Cell. Biochem. Funct., 29(5):384 93.doi.org/1‎‎0.1002/cbf.1761‎
  5. Asiedu, B., Anang, Y., Nyarko, A., Doku, D.A., Amoah, B.Y., ‎Santa, S., Ngala, R.A. and Asare, G.A. (2017). The role of ‎sex steroid hormones in benign prostatic hyperplasia. ‎Aging Male, 20(1), 17–22. ‎doi.org/10.1080/13685538.2016.1272101‎
  6. Bachman, E., Feng, R., Travison, T., Li, M., Olbina, G., Ostland, ‎V., Ulloor, J., Zhang, A., Basaria, S., Ganz, T., Westerman, ‎M. and Bhasin, S. (2010). Testosterone suppresses ‎hepcidin in men: a potential mechanism for testosterone-‎induced erythrocytosis. J. Clin. Endocrinol. Metab., 95(1‎‎0):4743-7. doi.org/10.1210/jc.2010-0864‎
  7. Bhambri, A., Srivastava, M., Mahale, V. G., Mahale, S. and ‎Karn, S. K. (2022). Mushrooms as potential sources of ‎active metabolites and medicines. Front. Microbiol., ‎‎13:837266. doi.org/10.3389/fmicb.2022.837266‎
  8. Chen, B., Cao, D., Chen, Z., Huang, Y., Lin, T., Ai, J., Liu, L. ‎and Wei, Q. (2020). Estrogen regulates the proliferation ‎and inflammatory expression of primary stromal cell in ‎benign prostatic hyperplasia. Transl. Androl. Urol., 9(2):3‎‎22-331.doi.org/10.21037/tau.2020.02.08‎
  9. Choi, Y. J., Kim, E. K., Fan, M., Tang, Y., Hwang, Y. J. and ‎Sung, S. H. (2019). Effect of ‎Paecilomycestenuipesextract on testosterone-induced ‎benign prostatic hyperplasia in sprague-dawley rats. Int. J. ‎Environ. Res. Public Health., 16(19):3764. ‎doi.org/10.3390/ijerph16193764‎
  10. Csikós, E., Horváth, A., Ács, K., Papp, N., Balázs, V. L., Dolenc, ‎M.S., Kenda, M., Kočevar Glavač, N., Nagy, M., Protti, ‎M., Mercolini, L., Horváth, G. and Farkas, Á. (2021). ‎Treatment of benign prostatic hyperplasia by natural ‎drugs. Molecules., 26(23), 7141. ‎doi.org/10.3390/molecules26237141‎
  11. De Nunzio, C., Presicce, F. and Tubaro, A. (2016). ‎Inflammatory mediators in the development and ‎progression of benign prostatic hyperplasia. Nat. Rev. ‎Urol., 13(10):613–626. doi.org/10.1038/nrurol.2016.168‎
  12. Delev, D.P., Davcheva, D.P., Kostadinov, I.D. and ‎Kostadinova, I.I. (2013). Effect of testosterone ‎propionate on ‎erythropoiesis after experimental orchiectomy. Folia. Med., 55(2):51-7. doi.org/10.2478/folmed-2013-0017‎
  13. Dong, X., Liao, Y., Chen, K., Fang, Y., Li, W., Chen, J., You, L. ‎and Li, S. (2015). Elevated red blood cell distribution ‎width in benign prostatic hyperplasia patients with ‎metabolic syndrome. Int. J. Clin. Exp. Med., 8(1):1213-9.‎
  14. Eleazu, C., Obianuju, N., Eleazu, K. and Kalu, W. (2017). The ‎role of dietary polyphenols in the management of erectile ‎dysfunction Mechanisms of action. Biomed. Pharmacother., 88: 644–652. doi.org/10.1016/j.biopha.2017.01.125‎
  15. Ghosh, S., Khatua, S., Dasgupta, A. and Acharya, K. (2021). ‎Crude polysaccharide from the milky mushroom, ‎Calocybe indica, modulates innate immunity of ‎macrophage cells by triggering MyD88-dependent ‎TLR4/NF-κB pathway. J. Pharm. Pharmacol.,73(1), 70–‎‎81. doi.org/10.1093/jpp/rgaa020‎
  16. Ghosh, S.K. (2015). Study of anticancer effect of Calocybe ‎indica mushroom on breast cancer cell line and human ‎Ewings sarcoma cancer cell lines. N. Y. Sci. J., 8: 10–5.‎
  17. Glina, S., Roehrborn, C. G., Esen, A., Plekhanov, A., Sorsaburu, ‎S., Henneges, C., Büttner, H. and Viktrup, L. (2015). ‎Sexual function in men with lower urinary tract ‎symptoms and prostatic enlargement secondary to ‎benign prostatic hyperplasia: results of a 6-month, ‎randomized, double-blind, placebo-controlled study of ‎tadalafil coadministered with finasteride. J. Sex. ‎Med., 12(1):129-38.12(1), 129–‎‎138.doi.org/10.1111/jsm.12714‎
  18. Grossmann, M. and Zajac, J. D. (2012). Hematological ‎changes during androgen deprivation therapy. Asian. J. ‎Androl., 14(2):187-192. doi.org/10.1038/aja.2011.102‎
  19. Hadwan, M. H. (2018). Simple spectrophotometric assay for ‎measuring catalase activity in biological tissues. BMC ‎Biochem., 19(1):7. doi.org/10.1186/s12858-018-0097-5‎
  20. Hassan, A.A. (2010). Effect of castration on some ‎physiological aspect in rats: Effect of testosterone ‎hormone. J. Educ. Sci. 23(3), 28-39.‎
  21. Higgins, T., Beutler, E. and Doumas, B.T. (2008). Measurement ‎of hemoglobin in blood. In: Burtis, C.A., Ashwood, E.R. ‎and Bruns, D.E., Eds., Tietz Fundamentals of Clinical ‎Chemistry, 6th Edition, Saunders Elsevier, Missouri. 514-‎‎515. ‎
  22. Homma, Y., Gotoh, M., Kawauchi, A., Kojima, Y., Masumori, ‎N., Nagai, A., Saitoh, T., Sakai, H., Takahashi, S., ‎Ukimura, O., Yamanishi, T., Yokoyama, O., Yoshida, M. ‎and Maeda, K. (2017). Clinical guidelines for male lower ‎urinary tract symptoms and benign prostatic hyperplasia. ‎Int. J. Urol., 24(10): 716-729.doi.org/10.1111/iju.13401‎
  23. Jeon, W. Y., Kim, O. S., Seo, C. S., Jin, S. E., Kim, J. A., Shin, H. ‎K., Kim, Y. U. and Lee, M. Y. (2017). Inhibitory effects of ‎Ponciri Fructus on testosterone-induced benign prostatic ‎hyperplasia in rats. BMC Complement. Altern. Med., ‎‎17(1):384. doi.org/10.1186/s12906-017-1877-y
  24. Jones, S. D., Jr, Dukovac, T., Sangkum, P., Yafi, F. A. and ‎Hellstrom, W. J. (2015). Erythrocytosis and polycythemia ‎secondary to testosterone replacement therapy in the ‎aging male. Sex. Med. Rev., 3(2):101-112. ‎doi.org/10.1002/smrj.43‎
  25. Kakkar, P., Das, B. and Viswanathan, P. N. (1984). A modified ‎spectrophotometric assay of superoxide dismutase. ‎Indian J BiochemBiophys., 21(2):130-2.‎
  26. Kalu, W. O., Okafor, P. N., Ijeh, I. I. and Eleazu, C. (2016). ‎Effect of kolaviron, a biflavanoid complex from ‎Garcinia kola on some biochemical parameters in ‎experimentally induced benign prostatic hyperplasic rats. ‎Biomed. Pharmacother., 83:1436–1443. ‎doi.org/10.1016/j.biopha.2016.08.064‎
  27. Kim, Y. N., Kim, M. S., Chun, S. S. and Choi, J. H. (2013). ‎Effect of Phelliuslinteus water extract on benign prostatic ‎hyperplasia. Nutr. Res. Pract., 7(3):172-177. ‎doi.org/10.4162/nrp.2013.7.3.172‎
  28. Ko, J. W., Park, S. W., Shin, N. R., Kim, W. I., Kim, J. C., Shin, I. ‎S. and Shin, D. H. (2018). Inhibitory effects of ‎Pycnogenol®, a pine bark extract, in a rat model of ‎testosterone propionate induced benign prostatic hyperplasia. Lab. Anim. Res., 34 (3):111-117. ‎doi.org/10.5625/lar.2018.34.3.111‎
  29. Kwon, Y. (2019). Use of saw palmetto (Serenoa repens) extract ‎for benign prostatic hyperplasia. Food Sci. Biotechnol., ‎‎28:1599-1606. doi.org/10.1007/s10068-019-00605-9‎
  30. La Vignera, S., Condorelli, R. A., Russo, G. I., Morgia, G. and ‎Calogero, A. E. (2016). Endocrine control of benign ‎prostatic hyperplasia. Androl., 4(3), 404–411. ‎https://doi.org/10.1111/andr.12186‎
  31. Langan, R.C. (2019). Benign prostatic hyperplasia. Prim. Care ‎Clin. Office Prac. 46:223–232. ‎
  32. Lepor, H. (2016). Alpha-blockers for the treatment of benign ‎prostatic hyperplasia. Urol. Clin. North Am., 43:311 23.d‎oi.org/10.1016/j.ucl.2016.04.009.‎
  33. Madersbacher, S., Sampson, N. and Culig, Z. (2019). ‎Pathophysiology of benign prostatic hyperplasia and ‎benign prostatic enlargement: A mini-review. Gerontol. ‎‎65:458-464.doi.org/10.1159/000496289‎
  34. Makchit, G. (2017). Prevalence of prostatic disorders in dogs in ‎Jos, Plateau State, Nigeria. Saudi J. Med. Pharm. Sci., ‎‎3:745-747.‎
  35. Minciullo, P. L., Inferrera, A., Navarra, M., Calapai, G., Magno, ‎C. and Gangemi, S. (2015). Oxidative stress in benign ‎prostatic hyperplasia: a systematic review. Urol. Int., ‎‎94:249–254. doi.org/10.1159/000366210‎
  36. Mitsunari, K., Miyata, Y., Matsuo, T., Mukae, Y., Otsubo, A., ‎Harada, J., Kondo, T., Matsuda, T., Ohba, K. and Sakai, ‎H. (2021). Pharmacological Effects and Potential Clinical ‎Usefulness of polyphenols in benign prostatic ‎hyperplasia. Molecules.,26(2), 450. ‎doi.org/10.3390/molecules26020450‎
  37. Nahata, A. and Dixit, V. K. (2012). Ganoderma lucidum is an ‎inhibitor of testosterone-induced prostatic hyperplasia in ‎rats. Andrologia., 44 Suppl 1:160-174. ‎doi.org/10.1111/j.1439-0272.2010.1155.x‎
  38. NRC. (2011).National Research Council. Committee for the ‎update of the guide for the care and use of laboratory ‎animals, guide for the care and use of laboratory animals, ‎‎8th edn. National Academies Press, Washington, DC.‎
  39. Ohkawa, H., Ohishi, N. and Yagi, K. (1979). Assay for lipid ‎peroxides in animal tissues by thiobarbituric acid reaction‎. Anal. Biochem., 95(2):351 8. doi.org/10.1016/0003 269‎‎7 (79)90738-3‎
  40. Ohlander, S.J., Varghese, B. and Pastuszak, A.W. (2018). ‎Erythrocytosis following testosterone therapy. Sex. ‎Med. Rev., 6(1):77-85. ‎doi.org/10.1016/j.sxmr.2017.04.001‎
  41. Olsen, N. J., Gu, X. and Kovacs, W. J. (2001). Bone marrow ‎stromal cells mediate androgenic suppression of B ‎lymphocyte development. J. Clin. Invest., 108(11):1697-‎‎704. doi.org/10.1172/JCI13183‎
  42. Patel, K. V., Semba, R. D., Ferrucci, L., Newman, A. B., Fried, L. ‎P., Wallace, R. B., Bandinelli, S., Phillips, C. S., Yu, B., ‎Connelly, S., Shlipak, M. G., Chaves, P. H., Launer, L. J., ‎Ershler, W. B., Harris, T. B., Longo, D. L. and Guralnik, J. ‎M. (2010). Red cell distribution width and mortality in ‎older adults: a meta-analysis. J. Gerontol. A Biol. Sci. ‎Med. Sci., 65: 258- 265.doi.org/10.1093/gerona/glp163‎
  43. Sánchez, C. (2016). Reactive oxygen species and antioxidant ‎properties from mushrooms. Synth. Syst. Biotechnol., 24; ‎‎2(1):13-22.doi.org/10.1016/j.synbio.2016.12.001‎
  44. Shashikant, M., Bains, A., Chawla, P., Fogarasi, M. and ‎Fogarasi, S. (2022). The Current Status, Bioactivity, Food, ‎and Pharmaceutical Approaches of Calocybe indica: A ‎Review. Antioxidants., 11(6), 1145. ‎doi.org/10.3390/antiox11061145‎
  45. Singh, R., Letai, A. and Sarosiek, K. (2019). Regulation of ‎apoptosis in health and disease: the balancing act of ‎BCL-2 family proteins. Nat. Rev. Mol. Cell. Biol., ‎‎20(3):175–193. doi.org/10.1038/s41580-018-0089-8‎
  46. Subbiah, K. A. and Balan, V. (2015). A comprehensive review ‎of tropical milky white mushroom (Calocybe indica ‎P&C). Mycobiol., 43(3), 184–194. ‎doi.org/10.5941/MYCO.2015.43.3.184‎
  47. Suvarna, S.K., Layton, C. and Bancroft, J.D. (2019).Bancroft's ‎Theory and Practice of Histological Techniques. Elsevier, ‎Oxford.‎
  48. Thrall, M.A.and Weiser, M.G. (2002). Haematology. In: ‎Hendrix CM, editor. Laboratory procedures for veterinary ‎technicians. 4th ed. Missouri: Mosby Inc. 29–74.‎
  49. Traish, A. M., Melcangi, R. C., Bortolato, M., Garcia-Segura, L. ‎M. and Zitzmann, M. (2015). Adverse effects of 5α-‎reductase inhibitors: What do we know, don't know, and ‎need to know?Rev. Endocr. Metab. Disord.,16:177-‎‎98.doi.org/10.1007/s11154-015-9319-y
  50. Tsikas, D. (2017). Assessment of lipid peroxidation by ‎measuring malondialdehyde (MDA) and relatives in ‎biological samples: Analytical and biological challenges. ‎Anal. Biochem., 524:13-30. ‎doi.org/10.1016/j.ab.2016.10.021‎
  51. Udensi, U. K. and Tchounwou, P. B. (2016). Oxidative stress in ‎prostate hyperplasia and carcinogenesis. J. Exp. Clin. ‎Cancer Res., 35(1):139. doi.org/10.1186/s13046-016-‎‎0418-8‎
  52. Wang, M. and Su, P. (2018). The role of the Fas/FasL signaling ‎pathway in environmental toxicant-induced testicular cell ‎apoptosis: An update. Syst. Biol. Reprod. Med., 64(2):93–‎‎102. doi.org/10.1080/19396368.2017.1422046‎
  53. Wasser, S. P. (2017). Medicinal mushrooms in human clinical ‎studies. Part I. Anticancer, oncoimmunological, and ‎immunomodulatory activities: A review. Int. J. ‎Med. Mushrooms., 19(4):279-317. ‎doi.org/10.1615/IntJMedMushrooms.v19.i4.10‎